Evaluating Drugs to Treat Hemangiosarcoma
Hemangiosarcoma remains one of the deadliest canine cancers. Despite treatments such as chemotherapy, immunotherapy and surgery, dogs rarely live beyond six months after diagnosis. New approaches are needed to improve the survival time of dogs afflicted with this devastating disease. This study will expand on the research team's previous research into a novel class of drugs called tyrosine kinase inhibitors that may have the potential to control the growth of hemangiosarcoma. The results will help to clarify abnormalities that contribute to hemangiosarcoma proliferation and may ultimately lead to new treatment options for this aggressive cancer.
Dr. Stuart C. Helfand, Oregon State University
Co-sponsors: Bernese Mountain Dog Club of America; Australian Shepherd Health and Genetics Institute (ASHGI); Blue Buffalo Foundation; Anonymous, for Chelsea “parted from me and never parted”; Portuguese Water Dog Foundation; The American German Shepherd Dog Charitable Foundation, Inc.; 4th BILBO BASH; Rainier Agility Team; Golden Retriever Foundation